Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWY003 for geographic atrophy secondary to age-related macular degeneration
CTR20262244Phase 2Active
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FWY003 in age-related macular degeneration (AMD), sponsored by Novartis. Started Jun 2026; status: active.
02
Drugs
FWY003
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20262244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262244.